Olmesartan Medoxomil Sandoz

Olmesartan Medoxomil, the active ingredient in Olmesartan Medoxomil Sandoz, is an Angiotensin II receptor blocker presented as an oral dosage form for oral use. It is employed to lower elevated blood pressure in adults with hypertension. GNH USA supplies Olmesartan Medoxomil Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan Medoxomil is an ARB that targets the renin‑angiotensin system to control high blood pressure. - Hypertension: reduces systolic and diastolic blood pressure in patients with essential hypertension. - Cardiovascular risk management: used as part of combination therapy to lower the risk of stroke and myocardial infarction in hypertensive patients. - Renal protection in hypertension: helps preserve kidney function by controlling blood pressure in patients with diabetic or non‑diabetic nephropathy.

Common Side Effects: - Dizziness: feeling light‑headed, especially after standing. - Headache: mild to moderate intensity. - Fatigue: general tiredness or lack of energy. - Nausea: occasional upset stomach. - Diarrhea: loose stools. - Hyperkalemia: elevated blood potassium levels.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat. - Acute renal failure: sudden decline in kidney function. - Severe hypotension: markedly low blood pressure causing fainting. - Hepatic injury: abnormal liver enzyme elevations. - Myocardial infarction: rare occurrence of heart attack. - Allergic rash: severe skin reactions such as Stevens‑Johnson syndrome.

Olmesartan Medoxomil should be used with careful monitoring and patient education. - Blood pressure monitoring: regularly check to avoid excessive hypotension. - Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. - Serum potassium: monitor for hyperkalemia, especially when combined with potassium‑sparing agents. - Hepatic impairment: use with caution in patients with liver disease. - Pregnancy: avoid use during pregnancy due to unknown safety. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan Medoxomil can interact with several drug classes that affect the renin‑angiotensin‑aldosterone system or potassium balance. Major Interactions (Avoid): - Aliskiren: concurrent use may increase risk of renal impairment and hyperkalemia. - ACE inhibitors: combined therapy can cause additive hypotension and renal dysfunction. - Potassium‑sparing diuretics: may precipitate dangerous hyperkalemia. - Lithium: can raise lithium levels, leading to toxicity. - NSAIDs (high dose): increase risk of renal injury.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance antihypertensive effect, requiring dose adjustment. - Cyclosporine: can raise serum creatinine, necessitating renal monitoring. - Rifampin: may reduce olmesartan plasma concentrations. - Digoxin: monitor for signs of toxicity when renal function changes. - Antidiabetic agents: blood glucose may improve, requiring dose review.